Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C A Briggs

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Clinical Anatomy (New York, N.Y.)|August 21, 2013
Anatomy and biomechanics of gluteus maximus and the thoracolumbar fascia at the sacroiliac jointP J Barker, K S Hapuarachchi, J A Ross, et al.
British Journal of Sports Medicine|November 25, 2004
Histology of the fascial-periosteal interface in lower limb chronic deep posterior compartment syndromeT D A Barbour, C A Briggs, S N Bell, et al.
British Journal of Pharmacology|December 1, 1991
Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393C A Briggs, N J Pollock, D E Frail, et al.
European Journal of Pharmacology|March 19, 1999
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variantC A Briggs, D G McKenna, L M Monteggia, et al.
Alzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.
Proceedings of the Western Pharmacology Society|January 1, 1995
Cholinergic channel activators: novel opportunities for the treatment of CNS disordersJ P Sullivan, M W Decker, D Donnelly-Roberts, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterizationS P Arneric, J P Sullivan, C A Briggs, et al.
British Journal of Pharmacology|December 25, 2007
alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analoguesC A Briggs, M R Schrimpf, D J Anderson, et al.
Journal of Physiology, Paris|October 28, 1998
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594M W Decker, P Curzon, M W Holladay, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 1998
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterizationD L Donnelly-Roberts, P S Puttfarcken, T A Kuntzweiler, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Clinical Anatomy (New York, N.Y.)|August 21, 2013
Anatomy and biomechanics of gluteus maximus and the thoracolumbar fascia at the sacroiliac jointP J Barker, K S Hapuarachchi, J A Ross, et al.
British Journal of Sports Medicine|November 25, 2004
Histology of the fascial-periosteal interface in lower limb chronic deep posterior compartment syndromeT D A Barbour, C A Briggs, S N Bell, et al.
British Journal of Pharmacology|December 1, 1991
Activation of the 5-HT1C receptor expressed in Xenopus oocytes by the benzazepines SCH 23390 and SKF 38393C A Briggs, N J Pollock, D E Frail, et al.
European Journal of Pharmacology|March 19, 1999
Gain of function mutation of the alpha7 nicotinic receptor: distinct pharmacology of the human alpha7V274T variantC A Briggs, D G McKenna, L M Monteggia, et al.
Alzheimer Disease and Associated Disorders|January 1, 1995
Potential treatment of Alzheimer disease using cholinergic channel activators (ChCAs) with cognitive enhancement, anxiolytic-like, and cytoprotective propertiesS P Arneric, J P Sullivan, M W Decker, et al.
Proceedings of the Western Pharmacology Society|January 1, 1995
Cholinergic channel activators: novel opportunities for the treatment of CNS disordersJ P Sullivan, M W Decker, D Donnelly-Roberts, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 1, 1994
(S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterizationS P Arneric, J P Sullivan, C A Briggs, et al.
British Journal of Pharmacology|December 25, 2007
alpha7 nicotinic acetylcholine receptor agonist properties of tilorone and related tricyclic analoguesC A Briggs, M R Schrimpf, D J Anderson, et al.
Journal of Physiology, Paris|October 28, 1998
The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594M W Decker, P Curzon, M W Holladay, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 15, 1998
ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I. In vitro characterizationD L Donnelly-Roberts, P S Puttfarcken, T A Kuntzweiler, et al.
Pageof 6